Asymmetric cinnamylation of N-tert-butanesulfinyl imines with cinnamyl acetates: total syntheses of (+)-lycoricidine and (+)-7-deoxypancratistatin
作者:Sen-Lin Cai、Bin-Hua Yuan、Yi-Xiang Jiang、Guo-Qiang Lin、Xing-Wen Sun
DOI:10.1039/c7cc00108h
日期:——
A highly diastereoselective palladium catalyzed cinnamylation of N-tert-butanesulfinyl imines with cinnamyl acetates has been established to provide enantioenriched [small beta]-aryl homoallylic amines. The synthetic application of this stragety has been successfully...
A chiralaldehyde is rationally combined with a Lewis acid and a transition metal for the first time to form a triple catalytic system. This cocatalytic system exhibits good catalytic activation and stereoselective-control abilities in the asymmetric α-allylation reaction of N-unprotected amino acid esters and allyl acetates. Optically active α,α-disubstituted α-amino acids (α-AAs) are generated in
Dual Ni/Organophotoredox Catalyzed Allylative Ring Opening Reaction of Oxabenzonorbornadienes and Analogs
作者:Abdoul G. Diallo、Déborah Paris、Djiby Faye、Sylvain Gaillard、Mark Lautens、Jean-Luc Renaud
DOI:10.1021/acscatal.2c00512
日期:2022.3.18
A general approach for the allylation of oxa- and azabenzonorbornadienes is reported by merging organophotoredox and nickel catalysis. This methodology allowed the diastereoselective allylation of various heterocyclic alkene derivatives with a broader range of allylic acetate compounds compared to previously published procedures. Moreover, no air-sensitive organometallic species and no metal reductants
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
申请人:Liu Hong
公开号:US20100234365A1
公开(公告)日:2010-09-16
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
申请人:Liu Hong
公开号:US08431607B2
公开(公告)日:2013-04-30
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).